Tag Archives: rare diseases

A Bright Future for Orphan Disease Indications

Chart

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved drugs in the BioMedTracker database with an orphan indication designation. Our research found that 2012 saw the greatest number of approvals of therapies for orphan indications going back all the way to 2000 (This count includes previously approved drugs with new, orphan indication approvals).   Overall, 24 therapies were approved in orphan indications last year, including drugs for Anthrax, Gaucher’s Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , ,

Navigating the Rare Disease World

Susan Ruediger

The international orphan drug marketplace is expected to grow some 30 percent by 2014, fueled by the entrance of big pharmaceutical companies and U.S. legislation favoring development and coverage. This growth promises to improve the health of patients with debilitating and life-threatening disorders. Hoping to further the rare disease dialogue and relationship building opportunities, the 2013 Orphan Disease Forum will provide unique perspective on the orphan drug marketplace, regulatory considerations and much more. Operating within Read More >

Events  |  2 Comments  |  Email This Post
Tags: , , , , , , , ,

Rare Disease Day: Families and Advocacy Groups Drive Treatments for Rare Diseases

Gavin and Bella Today, we celebrate Rare Disease Day to recognize the path to treatments and cures is paved by families and caregivers working with advocacy groups, medical advisors, and dedicated researchers. Of the many people touched by and involved in the world of rare diseases, patients and their families are inarguably the most passionate advocates for rare disease research. When their disease-focused family foundations work together, pool their funds, and align their efforts, the results can be Read More >
Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Orphan Drugs: Making Rare Diseases Rarer

Panel

A panel at the BIO CEO & Investor Conference provided an analysis of the thriving orphan drug market opportunity featuring industry, clinical and regulatory experts specializing in rare diseases. The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech

Tony Coles

After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most Influential People in Bipoharma Today,” N. Anthony (Tony) Coles, MD, Chairman & CEO of Onyx Pharmaceuticals sat down with Steve Usdin, Senior Editor of BioCentury for an early morning Fireside Chat at the 15th Annual BIO CEO & Investor Conference. To read more about Onyx’s stellar year and their company milestones, visit here. The biotech retained complete control in the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,